Rexlemestrocel-L

Drug Profile

Rexlemestrocel-L

Alternative Names: Allogeneic mesenchymal precursor cells - Mesoblast; CEP-41750; Mesenchymal stem cell therapy - Mesoblast; MPC 06; MPC-06-ID; MPC-150; MPC-150-IM; MPC-25; MPC-25-IC; MPC-300; MPC-300-IV; MPC-75-IA; MPC-CBE; MPC-MICRO-IO; MSB-CAR001; NeoFuse; Replicart; Revascor

Latest Information Update: 08 Mar 2017

Price : $50

At a glance

  • Originator Hanson Institute; Institute of Medical and Veterinary Science
  • Developer Angioblast Systems; Mesoblast; Teva Pharmaceutical Industries
  • Class Anti-inflammatories; Antihypercalcaemics; Antineoplastics; Antirheumatics; Heart failure therapies; Skin disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Osteogenesis stimulants; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological malignancies
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Heart failure; Intervertebral disc degeneration; Non-Hodgkin's lymphoma
  • Phase II Myocardial infarction; Osteoarthritis; Rheumatoid arthritis; Spondylosis; Type 2 diabetes mellitus
  • Phase I/II Diabetic nephropathies
  • Preclinical Age-related macular degeneration; Lung disorders
  • No development reported Fracture; Peripheral arterial disorders; Skin ulcer

Most Recent Events

  • 26 Feb 2017 Mesoblast in collaboration with the National Heart, Lung and Blood Institute of the National Institute of Health initiates a phase II trial in heart failure
  • 13 Feb 2017 Pharmacodynamics data from a preclinical study in Rheumatoid arthritis released by Mesoblast
  • 23 Dec 2016 Mesoblast and Mallinckrodt Pharmaceuticals enter into an agreeement for the development and commercialisation of Rexlemestrocel-L, worldwide excluding Japan and China for Intervertebral disc degeneration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top